Sensing from inside, not around.
Endoluminal sensing
Voyana measures from inside the GI tract itself — direct contact with the digestive environment, not an inferred signal through skin.
Multi-modal capsule
A single 12mm capsule integrates pH, pressure, temperature, and motion sensing in one ingestible platform.
Continuous, passive capture
Signal is captured automatically across the full 2–4 day Session — no manual logging required.
Research-informed algorithms
Gut Score and trigger-map models are built on the underlying clinical research, not a black-box heuristic.
Peer-reviewed. Independently validated.
Continuous monitoring of intra-abdominal pressure: cumulative pressure exposure predicts early acute kidney injury in animal model.
World Journal of Emergency Surgery, 2026.
Read the paper →Feasibility and accuracy of continuous intraabdominal pressure monitoring with a capsular device in human pilot trial.
Liao CH, Spain DA, Chen CC, Cheng CT, Lin WC, Ho DR, Lin HF, Catena F. World Journal of Emergency Surgery, 2025;20:7. (First-in-human clinical trial, co-led by Stanford Department of Surgery.)
Read the paper →Validation of continuous intraabdominal pressure measurement: feasibility and accuracy assessment using a capsular device in in-vivo studies.
Ho DR, Cheng CT, Ouyang CH, Lin WC, Liao CH. World Journal of Emergency Surgery, 2024;19(1):25.
Read the paper →An Ingestible Electronics for Continuous and Real-Time Intraabdominal Pressure Monitoring.
Liao CH, Cheng CT, Chen CC, Jow UM, Chen CH, Lai YL, et al. Journal of Personalized Medicine, 2021;11(1):12.
Read the paper →Award-winning innovation.
2nd Place — Wearable Technologies Innovation World Cup.
WT | Wearable Technologies, 2025.
Read more →Finalist — MEDICA Innovation World Cup.
MEDICA (Düsseldorf), 2024. Named to the Top 12 Health Techpreneurs of 2024.
Read more →Recognized across the industry.
Real-time wireless intra-abdominal pressure sensing capsule debuts at CES.
PR Newswire · CES 2021, January 2021.
Read the article →Real-time smallest wireless intra-abdominal pressure sensing capsule.
Meet Global (Business Next).
Read the article →Where the data comes from matters.
| Voyana | Suna (patch) | Throne (toilet camera) | |
|---|---|---|---|
| What it captures | The digestion process itself: pH, pressure, temperature, motility, from inside the GI tract | Gut sounds and heart-rate response through the skin | The output, photographed at the bowl |
| How often you learn | Continuously, across a 3–5 day Session | Continuously, during a 7-day wear period | Only when you use the toilet |
| Time to insight | Progressive, through and after the Session | Instant, in the app | A few minutes after the visit |
| Sensing depth | Endoluminal (medical-grade, direct contact) | Trans-abdominal (indirect, through skin) | Post-transit (after excretion) |
| Clinical validation | Peer-reviewed first-in-human trial (WJES, 2025), Stanford-co-led | No published clinical trial identified | No published clinical trial identified |
| Regulatory pathway | FDA 510(k) planned, ~12-month timeline | UK/EU regulatory advisory support | Consumer wellness only; no FDA pathway announced |
Comparisons based on publicly available product documentation as of mid-2026.
A one-off microbiome test shows what's living in a single sample. A patch listens through the skin and infers. Voyana measures the process as it happens, from inside.
Built to replace a catheter, not just to track bloating.
The underlying capsule technology started as an ICU problem, not a wellness idea. Monitoring intra-abdominal pressure in critical care traditionally meant a Foley catheter — invasive, prone to infection, inconsistent, and reliant on hours of manual staff work for readings that weren't even continuous. Starting in 2020, the technical team set out to replace it with something less invasive and more accurate: a wireless digital capsule for gastrointestinal monitoring.
Product design finalized and validated across more than 10 preclinical (animal) studies.
Pilot clinical study showed high correlation with traditional catheter-based measurements, confirming clinical accuracy.
The team is preparing the pivotal clinical trial required for FDA 510(k) clearance.
First-in-human. Peer-reviewed.
The capsule platform behind Voyana is already validated in a published clinical trial, co-led by Stanford's Department of Surgery.
Nearly four decades of FDA-cleared ingestibles.
Ingestible thermometer (NASA / Johns Hopkins). Adopted by the NFL and US military.
Capsule endoscopy (Given Imaging). Class II FDA clearance.
Wireless GI motility capsule (Medtronic). FDA-cleared.
Consumer vibrating capsule for chronic constipation. FDA-authorized.
Gas-sensing biomarker capsule (Atmo Biosciences). 510(k) cleared.
First-in-human results published, peer-reviewed in WJES, Stanford-co-led.
Three utility patents pending.
Filed across the capsule itself, how it senses motion in the body, and how it measures pressure.
Wireless capsule for wearable device calibration
Architecture and calibration methods for the ingestible capsule and its handoff to wearable systems.
Human-body motion sensing system
Detecting body motion and capsule transit signatures as the capsule moves through the GI tract.
Continuous intra-abdominal pressure
Turns bloating into a number — quantifying gas events, fermentation spikes, and meal-by-meal pressure response.
The evidence behind the product.
Peer-reviewed trial
A first-in-human study of the underlying capsule technology was peer-reviewed and published in the World Journal of Emergency Surgery, 2025, co-led with Stanford-affiliated researchers.
Three patents pending
Utility patent filings cover the capsule architecture, motion sensing, and pressure measurement systems.
FDA 510(k) pathway
Voyana is actively pursuing FDA 510(k) clearance, targeting roughly a 12-month timeline to bring the product to market safely.
Established ingestible precedent
Ingestible sensors have been an FDA-cleared category since CorTemp in 1988 — more than 5 million devices used safely to date.
Built with Stanford-Taiwan Biodesign
Core technical founders trained through the Stanford-Taiwan Biodesign program, alongside experience from Dexcom's CGM team and Google [x].
Not yet a medical device
Until FDA clearance, Voyana is offered as general wellness information, not a diagnostic tool. See the FAQ below for what that means in practice.
The science, the evidence, the boundaries.
A single ingestible capsule captures pH, pressure, temperature, and motility as it travels the GI tract over a 2–4 day session. That raw signal is processed into a daily Gut Score and personalized trigger maps showing which foods correlate with which symptoms.
The underlying sensing technology was validated in a peer-reviewed, first-in-human clinical study published in the World Journal of Emergency Surgery (2025), co-led with Stanford-affiliated researchers — not just internal testing.
Voyana's algorithms are designed to account for context (timing of meals, activity, sleep) rather than treat every signal in isolation. As with any physiological measurement, individual results can be influenced by multiple factors, which is part of why trigger maps are personalized rather than generic.
A CGM measures glucose in tissue, not digestion. A microbiome test is a one-time snapshot of stool composition that takes two to six weeks to return, and costs more to repeat. Voyana measures pH, motility, temperature, and pressure directly inside the GI tract, continuously, over a multi-day Session.
A peer-reviewed first-in-human trial of the core capsule technology, published in the World Journal of Emergency Surgery (2025). Three utility patents are pending on the capsule architecture, motion sensing, and pressure measurement.
Not yet. Voyana is actively pursuing FDA 510(k) clearance, targeting roughly a 12-month timeline. Until then, it is offered as general wellness information — not a diagnostic or medical device. It does not diagnose, treat, cure, or prevent any disease.
Full data handling and privacy details will be published alongside the app ahead of launch. Reach out at hello@voyanahealth.com with any questions in the meantime.
Be first to know.
Join the waitlist for updates as Voyana moves through FDA review toward a Q1 2027 launch.